Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 14/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475842 | 0.89 | GRIA4 (0.46) | GRIA4GRIA2GRIA1GRIA3TP53 | |
| SCHEMBL6473736 | 0.89 | GRIA4 (0.51) | CA2GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6480388 | 0.85 | GRIA4 (0.51) | GRIA4GRIA2GRIA1GRIA3TP53 | |
| SCHEMBL6475840 | 0.85 | CA2 (0.41) | CA2GRIA4PPARATP53 | |
| SCHEMBL6766018 | 0.85 | TP53 (0.44) | GRIA4GRIA2TP53 | |
| SCHEMBL6474222 | 0.84 | KIF11 (0.44) | CA2GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6482318 | 0.83 | GRIA4 (0.53) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6481138 | 0.80 | MTNR1A (0.50) | GRIA4 | |
| SCHEMBL6475304 | 0.80 | GRIA4 (0.47) | CA2GRIA4GRIA2GRIA1GRIA3 | |
| Hydrochloric Acid SCHEMBL6475275 | 0.79 | GRIA4 (0.46) | CA2GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1265857-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001068592-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225266-A1 | Sulfonamide derivatives | GRIN2A, GRM2, GRIA2 | CA2 1773/4885GRIA4 6/4885PPARA 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.